AR085302A1 - Metodo de produccion de anticuerpos sialilados - Google Patents

Metodo de produccion de anticuerpos sialilados

Info

Publication number
AR085302A1
AR085302A1 ARP120100573A ARP120100573A AR085302A1 AR 085302 A1 AR085302 A1 AR 085302A1 AR P120100573 A ARP120100573 A AR P120100573A AR P120100573 A ARP120100573 A AR P120100573A AR 085302 A1 AR085302 A1 AR 085302A1
Authority
AR
Argentina
Prior art keywords
antibody
domain
expressing
stirated
antibodies
Prior art date
Application number
ARP120100573A
Other languages
English (en)
Spanish (es)
Inventor
Beatrice Cameron
Bruno Genet
Fabienne Soubrier
Francis Blanche
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR085302A1 publication Critical patent/AR085302A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP120100573A 2011-02-24 2012-02-22 Metodo de produccion de anticuerpos sialilados AR085302A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305200 2011-02-24
EP11306090 2011-09-01

Publications (1)

Publication Number Publication Date
AR085302A1 true AR085302A1 (es) 2013-09-18

Family

ID=45774189

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100573A AR085302A1 (es) 2011-02-24 2012-02-22 Metodo de produccion de anticuerpos sialilados

Country Status (6)

Country Link
US (1) US20140046032A1 (https=)
EP (1) EP2678357A1 (https=)
JP (1) JP2014508759A (https=)
AR (1) AR085302A1 (https=)
TW (1) TW201241182A (https=)
WO (1) WO2012113863A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
EP2877589B1 (en) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
US9701753B2 (en) 2013-03-11 2017-07-11 Genzyme Corporation Hyperglycosylated binding polypeptides
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
ES2802274T3 (es) * 2013-05-02 2021-01-18 Momenta Pharmaceuticals Inc Glicoproteínas sialiladas
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
CA2908407C (en) 2013-05-29 2022-06-14 F. Hoffmann-La Roche Ag Quantitative control of sialylation
EP3017057B1 (en) 2013-07-05 2019-10-02 F.Hoffmann-La Roche Ag Process for the mono- and bi-sialylation of glycoproteins employing n-terminally truncated beta-galactoside alpha-2,6-sialyltransferase mutants
EP2824176A1 (en) 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057622A1 (en) * 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015143091A1 (en) 2014-03-19 2015-09-24 Genzyme Corporation Site-specific glycoengineering of targeting moieties
SG11201700446XA (en) 2014-07-21 2017-02-27 Glykos Finland Oy Production of glycoproteins with mammalian-like n-glycans in filamentous fungi
EP3037527A1 (en) * 2014-12-22 2016-06-29 F. Hoffmann-La Roche AG Sialyltransferase without CMP-dependent sialidase activity
WO2016102436A1 (en) 2014-12-22 2016-06-30 F. Hoffmann-La Roche Ag Cmp-dependent sialidase activity
JP7516047B2 (ja) 2016-11-23 2024-07-16 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤とｃｄ３８阻害剤とを含む医薬組み合わせ物及びその使用方法
EP3354278A1 (en) * 2017-01-31 2018-08-01 Sanofi Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide
FR3080376B1 (fr) * 2018-04-20 2022-12-09 Lab Francais Du Fractionnement Autoanticorps hautement sialyles et leurs utilisations
CN120192414A (zh) 2019-04-03 2025-06-24 建新公司 具有降低的断裂的抗αβTCR结合多肽
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
EP4430174A1 (en) * 2021-11-09 2024-09-18 Amgen Inc. Production of therapeutic proteins
WO2025101901A1 (en) * 2023-11-10 2025-05-15 The Board Of Trustees Of The Leland Stanford Junior University Use of sialylated ivig or igg fc region-containing protein for preventing or treating respiratory virus diseases

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5474896A (en) 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5830729A (en) 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
US20020045207A1 (en) * 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2414772C (en) 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
DE60236182D1 (de) 2001-09-14 2010-06-10 Cellectis Zufällige integration von polynukleotide nach in vivo linearisierung
EP3202899B1 (en) 2003-01-28 2020-10-21 Cellectis Custom-made meganuclease and use thereof
PT1896071E (pt) * 2005-06-30 2015-07-09 Janssen Biotech Inc Métodos e composições com melhorias na atividade terapêutica
SI1945665T1 (sl) 2005-10-21 2012-03-30 Genzyme Corp Terapevtska sredstva na osnovi protiteles s povečano ADCC aktivnostjo
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP1959996A2 (en) 2005-12-12 2008-08-27 AC Immune S.A. Monoclonal antibody
CA2647524C (en) 2006-04-05 2019-11-26 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AU2007317755A1 (en) 2006-10-27 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
JP2010512306A (ja) * 2006-10-27 2010-04-22 ザ ロックフェラー ユニバーシティー 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
AR063975A1 (es) * 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
MX338397B (es) 2007-08-29 2016-04-15 Sanofi Aventis Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso.
BRPI0818623A2 (pt) 2007-10-05 2017-05-23 Ac Immune Sa composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal
US20100074901A1 (en) 2007-10-15 2010-03-25 Marc Hubert Mercken Human anti-amyloid antibodies, compositions, methods and uses
US8586706B2 (en) 2007-10-25 2013-11-19 Kagoshima University Peptide vaccine using mimic molecules of amyloid β peptide
EP2205752B1 (en) 2007-10-25 2016-08-10 Sangamo BioSciences, Inc. Methods and compositions for targeted integration
EP2224000B1 (en) 2007-10-29 2020-05-13 TAO Health Life Pharma Co., Ltd. Antibody and use thereof
EP2207568B1 (en) 2007-11-16 2017-05-31 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
US8921523B2 (en) 2007-12-11 2014-12-30 Glaxo Group Limited Humanized anti-beta-amyloid antibodies
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
FR2945538B1 (fr) * 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
US10087236B2 (en) * 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering

Also Published As

Publication number Publication date
EP2678357A1 (en) 2014-01-01
WO2012113863A1 (en) 2012-08-30
US20140046032A1 (en) 2014-02-13
JP2014508759A (ja) 2014-04-10
TW201241182A (en) 2012-10-16

Similar Documents

Publication Publication Date Title
AR085302A1 (es) Metodo de produccion de anticuerpos sialilados
MX389743B (es) Proceso mejorado para la producción de oligosacáridos fucosilados.
BR112015031233A2 (pt) métodos de produção de derivados de ácidos graxos omega-hidroxilados
NZ630568A (en) Methods and means for the production of ch3 domain-comprising molecules
ZA201703241B (en) Anti-c5 antibodies and methods of use
PH12018501282A1 (en) Anti-c5 antibodies and methods of use
BR112016010340A2 (pt) novos métodos para se produzir tert ativa
BR112017021255A2 (pt) microrganismo modificado para a produção otimizada de 2,4-di-hidroxibutirato
MX2013014937A (es) Cultivo de celulas de mamifero.
EA201890345A2 (ru) Способ получения сахарного спирта из биомассы
MX353581B (es) Procesos para producir productos de fermentacion.
AU2011372711B2 (en) Method for processing mesenchymal stem cells and the use thereof in the treatment of diseases associated with oxidative stress
UA110946C2 (uk) Спосіб одержання лігніну
MX346518B (es) Metodos de desarrollo de variantes de terpeno sintasa.
BR112014026308A2 (pt) composições de cultura celular e métodos para produção de polipeptídeos
WO2011100477A3 (en) Antibodies and processes for preparing the same
AR096839A1 (es) Proceso mejorado para la producción de anticuerpos monoclonales
MX363690B (es) Expansión de celulas madre adultas in vitro.
WO2013041969A3 (en) Didemnin biosynthetic gene cluster in tistrella mobilis
MX2013011153A (es) Metodo para el analisis de conformacion por presion.
MX342235B (es) Metodo optimizado para captura de anticuerpo por cromatografia de modo mixto.
EP4446338A3 (en) Cells and method of cell culture
MX2019007411A (es) Reuso de enzimas en glucomanipulacion in vitro de anticuerpos.
BR112021024852A2 (pt) Métodos de cultura de célula e composições para produção de anticorpo
BR112015005081A8 (pt) Método para produzir um polissacarídeo capsular tendo um sorotipo de pneumococo

Legal Events

Date Code Title Description
FB Suspension of granting procedure